This Web Site is committed to the memory of Janis Morrow.
HCV News Archives Index
2001-2002
JANUARY 2002/2001
Hepatzyme: Saftey Analysis of Phase I Study
Man who came out on public TV dies at 50 Lilly and Vertex Pharmaceuticals Select Novel Oral Anti-Hepatitis C Summary of FDA Peg-Intron Hearing Expanding the Donor Pool with Living Donors
Hepatitis C Research Gets a Boost
1F7 Shows Positive Data for Hepatitis Heavy Demand Strains Schering? First Monoclonal Antibody to Show Activity Against The Hep C Virus
Research To Understand Poor Outcome In African-Americans/Asian
Liver Transplants
February 2002
Study: Hepatitis C Patients Infected After Age 30 Far More Likely to Develop Cirrhosis
Study: HAART Therapy Effective for Both Hepatitis C and HIV Patients
Bayer Seeks FDA Approval of Hepatitis C Test
Discovery Could One Day Lead to Genetic Treatment for Hepatitis C, Other Diseases
Study Set of Use of Human Liver Cells to Treat Cirrhosis Patients
Enbrel Helps Chronic Hepatitis C Patients With Rheumatoid Arthritis
SELECTED HIGHLIGHTS FROM THE DRAFT NIH HCV CONSENSUS STATEMENT
Roche's Hepatitis-C Drug Pegasys Gets EU Approval
Rigel to Present Update on Hepatitis C Drug Development Program
Paragraph IV Certification May Offer
Co-Exclusive Marketing Rights
August 2002
Review: New Edition of Living with Hepatitis C Offers Chapter on Pegylated Interferons
Hepatitis E Vaccine Recommended For Patients With Chronic Liver Disease
Clinical Trials of Monoclonal Antibody for HCV
Interferon Helps Prevent Liver-Related Deaths for Hepatitis C Patients
Chinese Drug Said Effective and Safe in Treating Chronic Hepatitis C
Once-Promising Drug Found Ineffective in Treating Hepatitis D
September 2002
The Business of Organ Transplants
Researchers develop model to predict post-transplant survival in liver transplant patients
New techniques may boost tolerance of donor organs
Early Study Results Show New Interferon Effective for Hepatitis C
Study Finding Pegylated Interferon Superior Said Flawed
Maxim Advances Enrollment of Ceplene Phase 2 Clinical Trial
Oklahoma Hospital Nurse Reused Needles on Patients
Deaths of Hepatitis C Patients in Japan Prompt Label Change in Rebetol
Pegasys + Ribavirin: study results published
October 2002
PEG-Intron Pen Introduced in Europe
Injection Drug Users Continue Risky Habits Even After Testing Positive for Hepatitis C Virus
Acetaminophen (Tylenol) Liver Damage "Is it safe for me to take Tylenol?"
VIRACEPT(R) Appears to be Generally Well Tolerated In Hepatitis-C Co-Infected Patients
Chronic or Primary HCV Infection
Risk of GI
symptoms with over-the-counter nonsteroidal anti-inflammatory drugs
FDA Meeting May Mean Roadblock for
Roche
Warning Issued on Reuse of Needles
InterMune, Inhale to develop hepatitis C drug
'Invisible Condom' May Prevent HIV and Herpes
Device extends liver cancer patients' lives-study
Spontaneous Recovery from Hepatitis C Infection Higher Than Thought
March 2002
America's Blood Centers Supports FDA Approval Of Nucleic Acid Testing
ICN Pharmaceuticals Defends Ribavirin Patient
EPA Approves Disinfectant to Fight Spread of Hepatitis B
Study: Hepatitis C Patients Not on Antiviral Therapy More Depressed
Roche Expects Approval of Pegasys in 2002
Study; Results Indicate New Drug Therapy Improves Adherence and Cure Rate
New Molecular Tests Make It Easier to Measure Hepatitis Viral Load
New Research Encouraging on Hepatitis B Combination Therapy
Rivarin-High Dose Interferon Combination Improves Responses In Hepatitis C
Pamela Anderson-Living with Hepatitis C
April 2002
Sharing Injection Equipment Spreads Hepatitis C
May 2002
2002 HCV Related Plenary Highlights from DDW
May News Stories 2002
European Hepatitis C Patients Sought for Phase II Trial of Ceplene in Combo Therapy
Study: Hereditary Hemochromatosis With Hepatitis C Ups Risk of Cirrhosis and Fibrosis
Study: Shorter Induction Combo Therapy Appears as Effective for Hepatitis C
Study: IND-6556 May Improve Liver Enzymes in Some Hepatitis C Patients
Study: Peg-Intron Superior to Colchicine for Hepatitis C Patients With Advanced Cirrhosis
Study: No Significant Difference in Side Effects for Weight-Based Doses of Rebetol
Hepatitis C May Be Transmitted Via Toothbrushes
Daily High-Dose Interferon Induction Therapy Not Advantageous in
Hepatitis C
Peginterferon Regimen Outperforms Standard
Treatment for Chronic Hepatitis C
Some Blood Donors Get Bad News
Discovers Novel Hepatitis 'C' Target; Drug Development Program
Quick Treatment Can Cure Hepatitis C
Drug May Limit Liver Damage Caused by Hepatitis C
"UNBUNDLED" REBETOL (RIBAVIRIN) FOR THE TREATMENT OF HEPATITIS C
New Treatment Stops Liver Scarring in Mice
November 2001